ISSN 1671-5411 CN 11-5329/R
Samuel J. Shubrooks. Stent, drug, polymer—enefits, risks, and opportunities. J Geriatr Cardiol 2006; 3(2): 71-72.
Citation: Samuel J. Shubrooks. Stent, drug, polymer—enefits, risks, and opportunities. J Geriatr Cardiol 2006; 3(2): 71-72.

Stent, drug, polymer—enefits, risks, and opportunities

  • Publish Date: 2006-06-28
  • It has been well established that use of drug-eluting stents has resulted in marked reduction in neointimal prolif-eration following stenting and that this is reflected clini-cally in a very significant decrease in late lumen loss, in-stent restenosis, and target lesion revascularization. This benefit occurs, however, in the setting of delayed endothe-lial and vascular wall healing with its potential for continu-ing thrombogenicity requiring more prolonged use of dual antiplatelet therapy to prevent stent thrombosis. Large se-ries of patients receiving sirolimus-eluting and paclitaxel-eluting stents have indicated the absence of any increase in adverse cardiac events up to one year following stenting. Questions have been raised, however, as to whether there may be any late "catch-up" in restenosis or in late stent thrombosis.
  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1675) PDF downloads(1581) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return